ISPOR-AC Lunchtime Webinar: Tumour Agnostic Therapies

Tumour Agnostic Therapies

ISPOR-AC Lunchtime Webinar series

Tuesday, 1st June @ 10:00am-12:00pm (AEST)

In the next decade, cancer care will be transformed as genomics enables increasingly personalised medicine. New tumour agnostic drugs will continue to enter the market in the future, increasing the demand on HTA assessment. Tumour agnostic drugs have specific challenges relating to multiple patient populations, non-comparative data and co-dependency with genetic testing. This session seeks to highlight some of the HTA challenges with tumour agnostic drugs as well as current and emerging HTA methodologies. A panel session will discuss policy implications.

Session 1:           Industry perspective (Carmel Spiteri, MSD)
Session 2:           Establishing the Value of Diagnostic and Prognostic Tests in Health Technology Assessment (Simon Walker, University of York)
Session 3:           Challenges with clinical evidence including basket/umbrella trials (Tracy Merlin; Adelaide Health Technology Assessment)
Session 4:           Modelling challenges with tumour agnostic therapies (Camille Schubert; Adelaide Health Technology Assessment)
Session 5:           Australian decision maker perspective (Andrew Wilson, University of Sydney)
Panel session:    Including speakers from Sessions 1-4. The panel will cover methodological and policy issues related to reimbursement of tumour agnostic therapies. This includes current challenges and future trends with technologies such as genomic screening.